Bill Gates says he's not 'a Mars person' like Elon Musk and would rather spend his money on vaccines than a trip to space
- Unlike fellow billionaire
Elon Musk, Bill Gatesdoesn't think going to Mars is all that important.
- Gates said he doesn't "think rockets are the solution," on Kara Swisher's "Sway" podcast.
- He'd rather dedicate funds to addressing climate and public health crises on Earth.
Tech tycoons Elon Musk and Jeff Bezos have dumped billions into private
The Microsoft cofounder explained why he hasn't gotten involved in Bezos and Musk's space race during an appearance on Kara Swisher's "Sway" podcast Monday."No, I'm not a Mars person. I know a lot of Mars people," he said. "I don't think rockets are the solution. But maybe I'm missing something there."
"I'm not going to pay a lot of money because my foundation can buy measles vaccines and save a life for $1,000," Gates said. "Anything I do, I always think, 'OK, I could spend that $1,000 buying measles vaccine.'"When it comes to addressing
"It's important to say that what Elon did with Tesla is one of the greatest contributions to climate change anyone's ever made," Gates said. "Underestimating Elon is not a good idea."Musk's interplanetary ambitions center around using rockets built by SpaceX, the space exploration company he founded in 2002, to transport 1 million people to Mars by 2050. Musk has said he aims to establish a self-sustaining city on the Red Planet so humanity can survive a future apocalypse on Earth. Amazon's founder and outgoing CEO, meanwhile, wants his firm, Blue Origin, to facilitate a base on the moon along with space colonies that could house up to 1 trillion people. Both SpaceX and Blue Origin are working to develop reusable rockets that would drastically cut the cost of a trip to space.
- Stocks to track on March 4 — HDFC, Airtel, Infosys, Adani Ports and others
- Deficit budget tabled in Arunachal Assembly with focus on
- DPR for piped water connection project announced in Rajasthan Budget to be ready by Aug 30: BD Kalla
- Budget session of Karnataka legislature to begin on Thursday
- Bharat Biotech’s Covaxin shows 81% efficacy after second dose in phase 3 trials